Equities research analysts expect Applied DNA Sciences, Inc. (NASDAQ:APDN) to post sales of $2.71 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Applied DNA Sciences’ earnings, with estimates ranging from $2.42 million to $3.00 million. Applied DNA Sciences reported sales of $550,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 392.7%. The firm is scheduled to issue its next quarterly earnings report on Thursday, May 13th.
On average, analysts expect that Applied DNA Sciences will report full year sales of $14.92 million for the current year, with estimates ranging from $10.44 million to $19.40 million. For the next financial year, analysts expect that the firm will report sales of $27.66 million, with estimates ranging from $23.32 million to $32.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Applied DNA Sciences.
Applied DNA Sciences (NASDAQ:APDN) last released its quarterly earnings data on Wednesday, February 10th. The technology company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.02). Applied DNA Sciences had a negative return on equity of 179.48% and a negative net margin of 672.79%. The business had revenue of $1.62 million for the quarter, compared to analyst estimates of $1.40 million.
APDN traded down $0.30 on Monday, reaching $7.10. The company’s stock had a trading volume of 169,476 shares, compared to its average volume of 1,463,127. The company has a market capitalization of $53.06 million, a price-to-earnings ratio of -2.06 and a beta of 1.40. Applied DNA Sciences has a fifty-two week low of $3.92 and a fifty-two week high of $16.39. The company has a quick ratio of 2.01, a current ratio of 2.13 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average of $8.53 and a two-hundred day moving average of $8.12.
Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. raised its position in Applied DNA Sciences by 6.0% in the 4th quarter. BlackRock Inc. now owns 87,319 shares of the technology company’s stock valued at $445,000 after purchasing an additional 4,964 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Applied DNA Sciences in the third quarter valued at about $78,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Applied DNA Sciences during the third quarter worth about $84,000. Orion Portfolio Solutions LLC purchased a new position in shares of Applied DNA Sciences during the fourth quarter worth about $65,000. Finally, Golden Green Inc. acquired a new position in Applied DNA Sciences in the 4th quarter valued at about $70,000. Institutional investors and hedge funds own 7.04% of the company’s stock.
Applied DNA Sciences Company Profile
Applied DNA Sciences, Inc develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes applications in the United States, Europe, and Asia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with MarketBeat.com's FREE daily email newsletter.